Trial Profile
A Randomized, Blinded, 12-week Comparison of Elvucitabine/Efavirenz/Tenofovir Versus Lamivudine/Efavirenz/Tenofovir in HIV-1 Infected Treatment-naive Participants. There is a 36 Week, Open-label, Extension Phase for Eligible Participants.
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 03 Nov 2023
Price :
$35
*
At a glance
- Drugs Elvucitabine (Primary) ; Efavirenz; Lamivudine; Tenofovir disoproxil fumarate
- Indications HIV-1 infections
- Focus Adverse reactions; Therapeutic Use
- Sponsors Achillion Pharmaceuticals; Alexion Pharmaceuticals
- 17 Feb 2010 96-week final results will be presented at the 17th Conference on Retroviruses and Opportunistic Infections, according to an Achillion Pharmaceuticals media release.
- 16 Feb 2010 96-week follow-up results presented at the 17th Conference on Retroviruses and Opportunistic Infections.
- 25 Aug 2009 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.